Exact Mass: 387.227

Exact Mass Matches: 387.227

Found 99 metabolites which its exact mass value is equals to given mass value 387.227, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

4-Hydroxytamoxifen

4-[(1Z)-1-{4-[2-(dimethylamino)ethoxy]phenyl}-2-phenylbut-1-en-1-yl]phenol

C26H29NO2 (387.2198)


4-Hydroxytamoxifen (Afimoxifene) is a metabolite of Tamoxifen. Afimoxifene (4-hydroxytamoxifen) is a selective estrogen receptor modulator which is the active metabolite of tamoxifen. Afimoxifene is a transdermal gel formulation and is being developed by Ascend Therapeutics, Inc. under the trademark TamoGel. (Wikipedia) D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D000970 - Antineoplastic Agents C1892 - Chemopreventive Agent

   

3-Hydroxytamoxifen (Droloxifene)

3-[(1E)-1-{4-[2-(dimethylamino)ethoxy]phenyl}-2-phenylbut-1-en-1-yl]phenol

C26H29NO2 (387.2198)


3-Hydroxytamoxifen (Droloxifene) is only found in individuals that have used or taken Tamoxifen. 3-Hydroxytamoxifen (Droloxifene) is a metabolite of Tamoxifen. 3-hydroxytamoxifen (droloxifene) belongs to the family of Stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D020011 - Protective Agents > D000975 - Antioxidants D000970 - Antineoplastic Agents C1892 - Chemopreventive Agent Same as: D03911

   

alpha-Hydroxytamoxifen

(3E)-4-{4-[2-(dimethylamino)ethoxy]phenyl}-3,4-diphenylbut-3-en-2-ol

C26H29NO2 (387.2198)


alpha-Hydroxytamoxifen is a metabolite of tamoxifen. Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a mixed agonist/antagonist. Tamoxifen is the usual endocrine therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting. (Wikipedia)

   

Tamoxifen N-oxide

2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine oxide

C26H29NO2 (387.2198)


Tamoxifen N-oxide is a metabolite of tamoxifen. Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a mixed agonist/antagonist. Tamoxifen is the usual endocrine therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting. (Wikipedia)

   

3-Hydroxydodec-6-enedioylcarnitine

3-[(11-Carboxy-3-hydroxyundec-6-enoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C19H33NO7 (387.2257)


3-Hydroxydodec-6-enedioylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxydodec-6-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxydodec-6-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Hydroxydodec-6-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

10-Hydroxydodec-9-enedioylcarnitine

3-[(11-carboxy-10-hydroxyundec-9-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H33NO7 (387.2257)


10-Hydroxydodec-9-enedioylcarnitine is an acylcarnitine. More specifically, it is an 10-hydroxydodec-9-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 10-Hydroxydodec-9-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 10-Hydroxydodec-9-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Hydroxydodec-5-enedioylcarnitine

3-[(11-carboxy-3-hydroxyundec-5-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H33NO7 (387.2257)


3-Hydroxydodec-5-enedioylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxydodec-5-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxydodec-5-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Hydroxydodec-5-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4E)-3-Hydroxydodec-4-enedioylcarnitine

3-[(11-carboxy-3-hydroxyundec-4-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H33NO7 (387.2257)


(4E)-3-Hydroxydodec-4-enedioylcarnitine is an acylcarnitine. More specifically, it is an (4E)-3-hydroxydodec-4-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4E)-3-Hydroxydodec-4-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (4E)-3-Hydroxydodec-4-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Hydroxydodec-9-enedioylcarnitine

3-[(11-carboxy-3-hydroxyundec-9-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H33NO7 (387.2257)


3-Hydroxydodec-9-enedioylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxydodec-9-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxydodec-9-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Hydroxydodec-9-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Hydroxydodec-8-enedioylcarnitine

3-[(11-Carboxy-3-hydroxyundec-8-enoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C19H33NO7 (387.2257)


3-Hydroxydodec-8-enedioylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxydodec-8-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxydodec-8-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Hydroxydodec-8-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

10-Hydroxydodec-10-enedioylcarnitine

3-[(11-Carboxy-10-hydroxyundec-10-enoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C19H33NO7 (387.2257)


10-Hydroxydodec-10-enedioylcarnitine is an acylcarnitine. More specifically, it is an 10-hydroxydodec-10-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 10-Hydroxydodec-10-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 10-Hydroxydodec-10-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Hydroxydodec-10-enedioylcarnitine

3-[(11-carboxy-3-hydroxyundec-10-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H33NO7 (387.2257)


3-Hydroxydodec-10-enedioylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxydodec-10-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxydodec-10-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Hydroxydodec-10-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Hydroxydodec-7-enedioylcarnitine

3-[(11-Carboxy-3-hydroxyundec-7-enoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C19H33NO7 (387.2257)


3-Hydroxydodec-7-enedioylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxydodec-7-enedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxydodec-7-enedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Hydroxydodec-7-enedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Fingolimod phosphate ester, S-

2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol monodihydrogen phosphate ester

C19H34NO5P (387.2174)


   

Afimoxifene

4-(1-{4-[2-(dimethylamino)ethoxy]phenyl}-2-phenylbut-1-en-1-yl)phenol

C26H29NO2 (387.2198)


   

Nufenoxole

2-[3-(5-methyl-1,3,4-oxadiazol-2-yl)-3,3-diphenylpropyl]-2-azabicyclo[2.2.2]octane

C25H29N3O (387.2311)


   

Tamoxifen-N-oxide

2-[4-(1,2-diphenylbut-1-en-1-yl)phenoxy]-N,N-dimethylethanamine oxide

C26H29NO2 (387.2198)


   

urapidil

6-({3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}amino)-1,3-dimethyl-1,2,3,4-tetrahydropyrimidine-2,4-dione

C20H29N5O3 (387.227)


C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents Urapidil is an α1 adrenoreceptor antagonist and a 5-HT1A receptor agonist.

   

urapidil

urapidil

C20H29N5O3 (387.227)


C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents Urapidil is an α1 adrenoreceptor antagonist and a 5-HT1A receptor agonist.

   
   
   

asparagylvalylarginine

asparagylvalylarginine

C15H29N7O5 (387.223)


   
   

arginylglycylarginine

arginylglycylarginine

C14H29N9O4 (387.2342)


   
   
   
   
   
   
   
   

valylasparagylarginine

valylasparagylarginine

C15H29N7O5 (387.223)


   
   
   

Fingolimod phosphate

Fingolimod phosphate

C19H34NO5P (387.2174)


   
   

4-hydroxytamoxifen

(E/Z)-4-hydroxy Tamoxifen

C26H29NO2 (387.2198)


CONFIDENCE standard compound; INTERNAL_ID 2716

   

Ala Ala Ala Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]propanamido]-5-carbamimidamidopentanoic acid

C15H29N7O5 (387.223)


   

Ala Ala Arg Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]propanamido]-5-carbamimidamidopentanamido]propanoic acid

C15H29N7O5 (387.223)


   

Ala Arg Ala Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-5-carbamimidamidopentanamido]propanamido]propanoic acid

C15H29N7O5 (387.223)


   

Gly Gly Arg Val

(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-5-carbamimidamidopentanamido]-3-methylbutanoic acid

C15H29N7O5 (387.223)


   

Gly Gly Val Arg

(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-3-methylbutanamido]-5-carbamimidamidopentanoic acid

C15H29N7O5 (387.223)


   

Gly Arg Gly Val

(2S)-2-{2-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanamido]acetamido}-3-methylbutanoic acid

C15H29N7O5 (387.223)


   

Gly Arg Val Gly

2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanamido]-3-methylbutanamido]acetic acid

C15H29N7O5 (387.223)


   

Gly Val Gly Arg

(2S)-2-{2-[(2S)-2-(2-aminoacetamido)-3-methylbutanamido]acetamido}-5-carbamimidamidopentanoic acid

C15H29N7O5 (387.223)


   

Gly Val Arg Gly

2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-methylbutanamido]-5-carbamimidamidopentanamido]acetic acid

C15H29N7O5 (387.223)


   
   
   
   
   
   

Arg Ala Ala Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]propanamido]propanamido]propanoic acid

C15H29N7O5 (387.223)


   

Arg Gly Gly Val

(2S)-2-(2-{2-[(2S)-2-amino-5-carbamimidamidopentanamido]acetamido}acetamido)-3-methylbutanoic acid

C15H29N7O5 (387.223)


   

Arg Gly Val Gly

2-[(2S)-2-{2-[(2S)-2-amino-5-carbamimidamidopentanamido]acetamido}-3-methylbutanamido]acetic acid

C15H29N7O5 (387.223)


   

Arg Val Gly Gly

2-{2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylbutanamido]acetamido}acetic acid

C15H29N7O5 (387.223)


   

Val Gly Gly Arg

(2S)-2-(2-{2-[(2S)-2-amino-3-methylbutanamido]acetamido}acetamido)-5-carbamimidamidopentanoic acid

C15H29N7O5 (387.223)


   

Val Gly Arg Gly

2-[(2S)-2-{2-[(2S)-2-amino-3-methylbutanamido]acetamido}-5-carbamimidamidopentanamido]acetic acid

C15H29N7O5 (387.223)


   

Val Arg Gly Gly

2-{2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-5-carbamimidamidopentanamido]acetamido}acetic acid

C15H29N7O5 (387.223)


   

FTY720 (R)-Phosphate

(2R)-amino-2-[2-(4-octylphenyl)ethyl]-1-(dihydrogen phosphate)-1,3-propanediol

C19H34NO5P (387.2174)


   

(S) FTY720 Phosphate

(2S)-amino-2-[2-(4-octylphenyl)ethyl]-1-(dihydrogen phosphate)-1,3-propanediol

C19H34NO5P (387.2174)


   

FTY720 phosphate

2-amino-2[2-(4-octylphenyl)ethyl]-1,3-propanediol, mono dihydrogen phosphate ester

C19H34NO5P (387.2174)


   

4-Hydroxytamoxifen

4-Hydroxytamoxifen

C26H29NO2 (387.2198)


   

tris(2-hydroxyethyl)ammonium decyl sulphate

tris(2-hydroxyethyl)ammonium decyl sulphate

C16H37NO7S (387.2291)


   
   

Nufenoxole

Nufenoxole

C25H29N3O (387.2311)


C78276 - Agent Affecting Digestive System or Metabolism > C266 - Antidiarrheal Agent

   

4-(3-ethoxycarbonylpiperidine)carboxamidophenylboronic acid, pinacol ester

4-(3-ethoxycarbonylpiperidine)carboxamidophenylboronic acid, pinacol ester

C21H30BNO5 (387.2217)


   

Tris dodecyl sulfate

Tris dodecyl sulfate

C16H37NO7S (387.2291)


   

1H-Benzimidazole,2-[1-[[1-(2-phenylethyl)-1H-tetrazol-5-yl]methyl]-4-piperidinyl]-(9CI)

1H-Benzimidazole,2-[1-[[1-(2-phenylethyl)-1H-tetrazol-5-yl]methyl]-4-piperidinyl]-(9CI)

C22H25N7 (387.2171)


   

(E)-4-HYDROXYTAMOXIFEN

(E/Z)-4-hydroxy Tamoxifen

C26H29NO2 (387.2198)


D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists D000970 - Antineoplastic Agents

   

6-[benzenesulfonyl(methyl)amino]hexanoic acid,N,N-dimethylpropane-1,3-diamine

6-[benzenesulfonyl(methyl)amino]hexanoic acid,N,N-dimethylpropane-1,3-diamine

C18H33N3O4S (387.2192)


   

2-Amino-1,5-dicyclohexyl-9,10-anthraquinone

2-Amino-1,5-dicyclohexyl-9,10-anthraquinone

C26H29NO2 (387.2198)


   

β-Methyl-γ-decalactone, mixt. with Phenylephrine hydrochloride (1:1)

β-Methyl-γ-decalactone, mixt. with Phenylephrine hydrochloride (1:1)

C20H34ClNO4 (387.2176)


   

Ethyl 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl)piperidine-3-carboxylate

Ethyl 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl)piperidine-3-carboxylate

C21H30BNO5 (387.2217)


   

4-[(1E)-1-{4-[2-(Dimethylamino)ethoxy]phenyl}-1-phenylbut-1-en-2-yl]phenol

4-[(1E)-1-{4-[2-(Dimethylamino)ethoxy]phenyl}-1-phenylbut-1-en-2-yl]phenol

C26H29NO2 (387.2198)


   

L-Arginine, glycyl-L-arginyl-

L-Arginine, glycyl-L-arginyl-

C14H29N9O4 (387.2342)


   

Droloxifene

3-Hydroxytamoxifen

C26H29NO2 (387.2198)


D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D020011 - Protective Agents > D000975 - Antioxidants D000970 - Antineoplastic Agents C1892 - Chemopreventive Agent Same as: D03911

   

2-[4-[(E)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine oxide

2-[4-[(E)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine oxide

C26H29NO2 (387.2198)


   

3-Hydroxydodec-6-enedioylcarnitine

3-Hydroxydodec-6-enedioylcarnitine

C19H33NO7 (387.2257)


   

3-Hydroxydodec-5-enedioylcarnitine

3-Hydroxydodec-5-enedioylcarnitine

C19H33NO7 (387.2257)


   

3-Hydroxydodec-9-enedioylcarnitine

3-Hydroxydodec-9-enedioylcarnitine

C19H33NO7 (387.2257)


   

3-Hydroxydodec-8-enedioylcarnitine

3-Hydroxydodec-8-enedioylcarnitine

C19H33NO7 (387.2257)


   

3-Hydroxydodec-7-enedioylcarnitine

3-Hydroxydodec-7-enedioylcarnitine

C19H33NO7 (387.2257)


   

10-Hydroxydodec-9-enedioylcarnitine

10-Hydroxydodec-9-enedioylcarnitine

C19H33NO7 (387.2257)


   

3-Hydroxydodec-10-enedioylcarnitine

3-Hydroxydodec-10-enedioylcarnitine

C19H33NO7 (387.2257)


   

10-Hydroxydodec-10-enedioylcarnitine

10-Hydroxydodec-10-enedioylcarnitine

C19H33NO7 (387.2257)


   

(4E)-3-Hydroxydodec-4-enedioylcarnitine

(4E)-3-Hydroxydodec-4-enedioylcarnitine

C19H33NO7 (387.2257)


   
   
   

N-[2-[1-[(E)-3-phenylprop-2-enyl]benzimidazol-2-yl]ethyl]cyclohexanecarboxamide

N-[2-[1-[(E)-3-phenylprop-2-enyl]benzimidazol-2-yl]ethyl]cyclohexanecarboxamide

C25H29N3O (387.2311)


   
   
   
   
   
   
   

Afimoxifene

(E/Z)-4-hydroxy Tamoxifen

C26H29NO2 (387.2198)


A tertiary amino compound that is tamoxifen in which the phenyl group which is in a Z- relationship to the ethyl substituent is hydroxylated at the para- position. It is the active metabolite of tamoxifen. D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D020847 - Estrogen Receptor Modulators D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D000970 - Antineoplastic Agents C1892 - Chemopreventive Agent

   

alpha-Hydroxytamoxifen

alpha-Hydroxytamoxifen

C26H29NO2 (387.2198)


   

Tamoxifen N-oxide

Tamoxifen N-oxide

C26H29NO2 (387.2198)


A tertiary amine oxide resulting from the formal oxidation of the amino group of tamoxifen.